Pharmsynthez intends to invest RUB 1.3 billion in its production facility in Bratsk, Russia. It is expected that the production of tuberculosis treatments and antivirals will begin in the first quarter of 2017, with the production of oncology products set to commence in 2018. The facility will reportedly have the capacity to manufacture 100 tonnes of drugs on an annual basis.